For example, osimertinib first received FDA approval in November 2017 for epidermal growth factor receptor (EGFR) T790M variant–positive non–small cell lung cancer (NSCLC) and received supplementary approval in April 2018 as a first-line therapy for NSCLC with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution.5 Efficacy in the front-line setting was established in the randomized, double-blind, active-controlled FLAURA study,6 in which patients were randomized to receive either osimertinib or erlotinib/gefitinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.